News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
FDA
Zeltia Group’s Yondelis to be Sold in Switzerland
February 6, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Feb 6 (Reuters) - Spanish biotechnology company Zeltia's (ZEL.MC) Yondelis drug has received approval to be sold in Switzerland to treat soft tissue sarcoma (STS), the company said in a statement on Friday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
July 15, 2025
·
2 min read
·
Tristan Manalac
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
·
1 min read
·
Tristan Manalac
